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Abstract 
Background: Cell-based therapies have the potential to become treatment options for many diseases, but efficient 
scale-out of these therapies has proven to be a major hurdle. Bioreactors can be used to overcome this hurdle, but 
changing the culture method can introduce unwanted changes to the cell product. Therefore, it is important to 
establish parity between products generated using traditional methods versus those generated using a bioreactor.
Methods: Mesenchymal stromal cells (MSCs) are cultured in parallel using either traditional culture flasks, spinner 
vessels or a new bioreactor system. To investigate parity between the cells obtained from different methods, har-
vested cells are compared in terms of yield, phenotype and functionality.
Results: Bioreactor-based expansion yielded high cell numbers (222–510 million cells). Highest cell expansion was 
observed upon culture in flasks [average 5.0 population doublings (PDL)], followed by bioreactor (4.0 PDL) and spin-
ner flasks (3.3 PDL). Flow cytometry confirmed MSC identity  (CD73+,  CD90+ and  CD105+) and lack of contaminating 
hematopoietic cell populations. Cultured MSCs did not display genetic aberrations and no difference in differentiation 
and immunomodulatory capacity was observed between culture conditions. The response to IFNγ stimulation was 
similar for cells obtained from all culture conditions, as was the capacity to inhibit T cell proliferation.
Conclusions: The new bioreactor technology can be used to culture large amounts of cells with characteristics 
equivalent to those cultured using traditional, flask based, methods.
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Background
Cell-based therapies have the potential to become treat-
ment options for many diseases [1], but efficient scale-
out of these therapies has proven to be a major hurdle 
[2, 3]. The production of adherent cells for therapeu-
tic purposes is particularly difficult, due to the need for 
a large surface area to expand cells to clinically relevant 
numbers. Traditionally, adherent cell expansion for 
clinical application involves cell culture in large num-
bers of flasks in incubators installed in cleanroom facili-
ties. This method requires heavy operator involvement as 
the culture needs to be seeded, refreshed, passaged and 
harvested individually and manually. The high costs of 
cell production in flasks poses a risk to the commercial 
viability of these cell-based therapies by jeopardizing the 
positive outcome of a cost–benefit assessment, which is 
necessary for therapy reimbursement [4]. Consequently, 
the need for more efficient culture methods that would 
enable a widespread deployment of cell therapies is well 
established [5].
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Several alternatives that aim to address the specific 
problems associated with flask culture have come to mar-
ket. These include stacked and multi-layered flask sys-
tems, as well as various bioreactor systems.
The use of bioreactors reduces the amount of labour 
and allows more space-effective production. Moreover, 
the use of closed systems enables cell therapy medicinal 
product (CTMP) manufacturing in environments with 
less stringent good manufacturing practise (GMP) clas-
sification thereby reducing production costs, compared 
to expansion using flasks. However, changing the culture 
methods can introduce changes to the characteristics 
and functionality of the cell products [6], as the proper-
ties of the cell product may change upon minor changes 
in cell manipulation. Therefore, it is crucial to investigate 
whether proposed new culture methods result in a prod-
uct that is comparable in terms of identity, safety and 
potency [7].
Mesenchymal stromal cells (MSCs) are currently inves-
tigated for clinical application in numerous trials render-
ing this adherent cell population highly relevant for cell 
therapy manufacturing using bioreactors. Here we inves-
tigate the possibility to efficiently generate MSCs using 
a novel, closed bioreactor system (Scinus), designed for 
automated cell expansion. We compared the character-
istics of MSC populations produced with three differ-
ent culture methods. We expanded MSCs on dissolvable 
microcarriers in the Scinus and in spinner flasks—which 
are a down-scaled model for bioreactor culture- and 
compared this to the traditional flask-based MSC pro-
duction method. The comparison included MSC expan-
sion potential and key attributes of the resulting cell 
populations. The expansion potential was assessed in 
MSC cultures where the MSCs were expanded to thera-
peutic relevant numbers (typically multiple infusions at a 
dose range of 1–2 millions of cells per kg of recipient’s 
body weight, amounting to several hundred millions of 
cells). MSCs have been attributed many functional prop-
erties [8]. They can modulate immune responses [9], 
secrete various factors contributing to tissue repair [10] 
and can be differentiated towards relevant cell types for 
tissue replacement [11]. Since the immunomodulatory 
properties of MSCs are widely recognised and are fre-
quently included in the proposed mechanisms of action 
for various therapeutic effects [12], we focus on these 
immunomodulatory properties and the responsiveness to 
inflammatory cytokines as indicators for the therapeutic 
potential of the MSCs.
For one CTMP manufacturing process to be replaced 
by another, parity between the cell products from both 
processes needs to be established [7]. We demonstrate 
that these bioreactor-expanded MSC populations are 
phenotypically similar to flask- and spinner-expanded 
MSC populations and are functionally equivalent. 
Expansion in the bioreactor yields clinically relevant cell 
numbers.
Methods
Bone marrow processing, MSC pre-culture, parallel 
expansion in flasks, spinners and in the Scinus bioreactor, 
cell harvest and microscopic inspection of the expanded 
cells was performed at Scinus Cell Expansion BV. All cel-
lular and molecular analyses of the resulting MSC pop-
ulations were independently performed at the Leiden 
University Medical Centre.
The Scinus cell expansion bioreactor
The Scinus Cell Expansion system was developed for 
the controlled expansion of cells. For the expansion of 
adherent cells, such as MSCs, microcarriers are used. 
The system consists of a single-use cell culture bag which 
is placed on a platform inside the hardware enclosure 
(Fig. 1a, b). The platform can rotate along its longitudinal 
axis at predefined speeds and intervals, thus maintaining 
a homogeneous cell suspension. The bag is coupled to a 
tubing system for the addition of fresh medium and the 
removal of waste medium (Fig. 1c). The medium is per-
fused through an oxygenation system that controls the 
dissolved oxygen (DO) and pH as measured by chemi-
cal optical sensors (PreSens GmbH, Regensburg, Ger-
many) that are incorporated in the bag. The temperature 
of the culture environment is controlled by the hardware 
enclosure. The system maintains a closed environment, 
and the addition (e.g. of fresh medium) and removal (e.g. 
sampling of cell suspensions or spent medium) is per-
formed through tube welding. Furthermore, the Scinus 
features an option to expand the volume of the bioreactor 
bag, ranging from 100 to 1400 mL.
Isolation and pre‑culture of bone marrow‑derived MSCs
Bone marrow biopsies were obtained from patients 
undergoing total hip replacement surgery. These biop-
sies were taken at the St. Antonius hospital, Utrecht, 
The Netherlands, after written informed consent was 
obtained. Ethical approval for this study was granted 
by the local medical ethics committee (study reference 
41885.100.12 R12.037/BOBI).
The bone marrow aspirate was filtered through a 
100  μm cell strainer (Merck/Millipore) and diluted 
1:1 with phosphate buffered saline (PBS, Westburg). 
Next, mononuclear cells (MNC) were obtained by den-
sity centrifugation using Lymphoprep density gradient 
medium according to the manufacturer’s protocol (Axis 
Shield) and seeded at approximately 160,000 cells/cm2 in 
T-flasks (Greiner) in hMSC medium. The hMSC medium 
consisted of alpha-MEM (Westburg), 15% fetal bovine 
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serum (FBS, Invitrogen), 1 ng/mL basic fibroblast growth 
factor (bFGF, Serotec), 2 mM GlutaMAX-I (Invitrogen), 
0.2  mM ascorbic acid-2-phosphate (Sigma-Aldrich) and 
100 U/100  μL penicillin/streptomycin (Invitrogen). The 
medium was refreshed every 2–3  days. Cells were har-
vested (passage 1) at 70–80% confluency, resuspended in 
freezing medium [hMSC medium with 30% FBS and 10% 
dimethylsulfoxide (DMSO)] and stored in liquid nitrogen 
until further use.
Cells were thawed, seeded at 400 cells/cm2 in T-flasks 
and cultured in hMSC medium for one passage. The cells 
were harvested (passage 2) at 70–80% confluency. After 
harvesting, the cells were used for parallel cultures in 
either T-flasks (Flask), spinner (Spinner) or the Scinus 
Cell Expansion system (Scinus).
Microcarrier suspension
For Scinus- and spinner-expansion, denatured collagen-
coated, dissolvable microcarriers (DMC) were used 
(Corning Life Sciences). These microcarriers have a sur-
face area of 5000  cm2/g. They were prepared according 
to the manufacturer’s instructions and stored as a stock 
solution at 5.0 g/L in hMSC medium.
Parallel expansion procedures
All expansion procedures were maintained for a total 
of 6  days, after which cells were harvested for various 
analyses.
Flask expansion
Monolayer cultures were seeded at 400 cells/cm2 in 
T-flasks in hMSC expansion medium. The flasks were 
kept in a standard incubator at 37 °C, 5%  CO2 and 100% 
humidity. The medium was refreshed every 2–3 days.
Spinner expansion
Spinners (BellCo) were prepared with 50  mL of micro-
carrier suspension and inoculated with 1.25 million cells 
(25,000  cells/mL, 1000  cells/cm2). Overnight seeding 
and subsequent expansion was performed with 9 cycli of 
continuous agitation at 35 RPM for 7 h, followed by a 1 h 
static interval to facilitate attachment of the cells. After 
3 days, the concentration of microcarriers was increased 
to 10  g/L and the static interval was removed. Spin-
ners were kept in a standard incubator at 37 °C, 5%  CO2 
and 100% humidity. The medium was refreshed every 
2–3 days.
Scinus expansion
One day prior to cell seeding, a Scinus Cell Expansion 
system (Scinus Cell Expansion BV, Bilthoven, The Neth-
erlands) was prepared as follows. A single-use bioreactor 
bag was filled with approximately 800  mL of microcar-
rier suspension. The culture environment was primed 
overnight to reach setpoints of 75% DO, pH 7.3, and a 
temperature of 37 °C. After priming, a total of 20 million 
MSCs was inoculated (25,000 cells/mL, 1000 cells/cm2). 
Fig. 1 Overview of the Scinus bioreactor system. a Scinus Bioreactor cabinet, b single-use bioreactor bag and c a schematic representation of the 
Scinus bioreactor system. 1: pH sensor, 2: DO sensor, 3: DO control section of the oxygenator, 4: pH control section of the oxygenator, 5: sample port
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A homogeneous suspension was maintained by rocking 
the bioreactor bag for 7 h followed by a 1 h static inter-
val. The settings for agitations are shown in Table 1. Dur-
ing the first 24 h, the system was not perfused and only 
temperature was controlled. Thereafter, perfusion was 
started at 2  mL/min in order to maintain setpoints for 
DO and pH. After 3 days, the concentration of microcar-
riers was increased to 10 g/L and the static interval was 
removed.
Harvest
Cells were harvested using 1× TrypLE (Invitrogen) for 
15 min. The microcarriers in spinner and Scinus cultures 
were subsequently dissolved for 15 min using a dedicated 
harvest solution consisting of PBS with pectinase (Sigma) 
and EDTA (0.5 M pH 8.0, Corning Life Sciences) at final 
concentrations of 100 U/mL and 10  mM respectively. 
Dissolution resulted in a single-cell suspension. The cells 
were washed in PBS and stored at − 80  °C in freezing 
medium (hMSC medium with 30% FBS and 10% DMSO) 
until analysis in various assays.
Analyses
Expansion
Microscopic inspection was performed daily to monitor 
the morphology of cells in T-flasks and on microcarriers. 
In addition, cell counts were performed at least on day 4 
and 6 for flask and spinner cultures, and every 1–2 days 
for Scinus cultures. Population doubling levels at harvest 
 (PDLharvest) were calculated according to the following 
formula:
where  Charvest is the total cell number at harvest,  Cseed is 
the number of cells seeded.
PDLharvest =
ln(Charvest/Cseed)
ln(2)
,
Surface marker expression
Expression of surface markers was determined on cell 
samples that were cryopreserved on day 6. Cells were 
thawed and evaluated for the following markers: CD73, 
CD105, CD90, CD45 and CD3. Data acquisition was per-
formed on a FACSCanto using Diva-software (BD Bio-
sciences, Erebodegem, Belgium). The data was analysed 
using Flow-jo software.
Karyotyping
The cells were seeded in culture flasks to stimulate prolif-
eration. After treatment with colcemid (4-6 h at 0.15 μg/
mL) the cells were detached using trypsin and concen-
trated by centrifugation. The cells were treated with 
hypotonic solution (75  mM KCl, 3  min), concentrated 
again and fixed with 10 volumes fixative 1 [methanol-
acetic acid 9:1 (v/v)]. The cells were concentrated and 
subsequently fixed with 10 volumes fixative 2 [methanol-
acetic acid 3:1 (v/v)]. The fixed cell suspension was con-
centrated once more after which the cells were dropped 
onto microscope slides. The slides were allowed to dry 
and aged overnight at 60 °C. The slides were re-hydrated 
in 2× SSC and subsequently in PBS, treated with trypsin 
(0.07%, 3  min) and finally stained at room temperature 
for 3–4 min according to Giemsa-Leishman (G-banding) 
using 1  ml Giemsa (Merck) and 3  mL Leishman stain 
(Merck) in 60  ml Gurr buffer (Gibco). The slides were 
dried and mounted in  Eukitt®.
Stimulation assays
MSCs generated by all three expansion methods were 
thawed, subcultured in flasks at a concentration of 4000 
cells per  cm2 and harvested when at least 80% conflu-
ence was reached. One day prior to stimulation 50,000 
MSC/well were seeded in hMSC medium in a 12-well 
plate (Corning, United States). MSCs were stimu-
lated for a total of 48  h with IFNγ (Peprotech, London, 
UK) at a concentration of 10  ng/mL. At 30  h into the 
Table 1 Settings for the dynamic agitation platform of the Scinus cell expansion system
Parameter Dimension Setting Description
Max angle Degrees (°) 180 Maximum rotation angle of the platform along its longitudinal axis. 180° results in a 
completely vertical position on both sides
Speed (°/second) 90 Speed of rotation of the platform along its longitudinal axis
Acceleration (°/second2) 90 Acceleration of the platform until the designated speed is achieved
Deceleration (°/second2) 90 Deceleration of the platform until the speed is 0°/s
Vertical pause (seconds) 10 Vertical hold time when the rotation has achieved the maximum angle, after which 
the platform rotates in the opposite direction. Used to let microcarriers settle and 
minimize shear
Horizontal pause (time, e.g. hours) One hour pause after 
every 7 h of agita-
tion
Hold time in horizontal (rest) position, used to optimise bead-to-bead transfer
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MSC-stimulation, Monensin protein transport inhibi-
tor (BD Biosciences, Breda, the Netherlands) was added 
according manufacturer’s instructions and stimulation 
continued for the remaining 18  h. Next, expression of 
indoleamine 2,3-dioxygenase (IDO) and CD274 was 
evaluated using flow cytometry. Data acquisition was 
performed on a FACSCanto using Diva-software (BD 
Biosciences, Erebodegem, Belgium). The data was ana-
lysed using Flow-jo software.
Inhibition of T cell proliferation
The capacity of MSCs to inhibit T cell proliferation was 
tested in a co-culture of MSCs with peripheral blood 
mononuclear cells (PBMCs). MSCs were plated in graded 
doses in a 96-well V-bottomed plate in RPMI 1640 sup-
plemented with 10% FBS and penicillin/streptomycin 
(all from Thermo Fisher Scientific). PBMCs (1.0 × 105/
well) were added and stimulated with human T-activator 
CD3/CD28 Dynabeads (Thermo Fisher Scientific) in a 
bead:PBMC ratio of 1:5. The co-cultures were incubated 
for 6  days at 37  °C, where 3H-thymidine was added for 
the last 16  h. 3H-Thymidine incorporation was meas-
ured on an oscillation counter (MSD Nordian) and data 
was expressed as a percentage of the positive control (no 
MSC). The heatmap and the Pearson correlation average-
linkage analysis-based hierarchical clustering was per-
formed with the TM4 MeV Stand-Alone Client [13].
Differentiation assays
Tri-lineage differentiation was assessed for cells seeded 
directly from cryopreservation. Adipogenic differen-
tiation was performed using the MesenCult Adipogenic 
Differentiation Kit (Stemcell Technologies) according to 
the manufacturer’s instructions. Similarly, chondrogenic 
differentiation was done using the MesenCult Chondro-
genic Differentiation Kit (Stemcell Technologies) accord-
ing to the manufacturer’s instructions. The osteogenic 
differentiation protocol consisted of 25–28 day culture on 
hMSC medium with the addition of β-glycerolphosphate 
(0.01  M) and dexamethasone  (10−8M). For adipogenic 
differentiation, presence of lipid vacuoles was dem-
onstrated using Oil Red O staining. For chondrogenic 
differentiation, presence of aggrecan was demonstrated 
using Alcian Blue staining. For osteogenic differentiation, 
calcium deposits were stained with Alizarin Red.
Statistics
Matched-samples ANOVA was performed to test for 
difference in CD73, CD90 and CD105 expression. The 
Friedman test was performed to determine the effect of 
the expansion method on IFNγ-induced upregulation of 
CD274 and IDO expression. The Kruskal–Wallis test was 
performed to determine the effect of donor background.
Results
Initiation of bone marrow culture
MSC cultures were initiated from bone marrow aspi-
rates derived from five different donors. Average donor 
age was 65.4  years (range 57–82  years) with three male 
and two female donors. Biopsies were small (range 
6.1–13.0  mL) and white blood cell counts ranged from 
8.5 × 106 to 28.3 × 106 cells/mL. Donor and biopsy infor-
mation is summarised in Table 2.
Characterisation of flask, spinner and Scinus cultures
Cell expansion
Each single-donor BM-derived MSC population was par-
allel-cultured in flasks and on microcarriers in both the 
Scinus and in a spinner. All cultures were evaluated for 
cell numbers at multiple time points. To directly compare 
the cell yields to the Scinus cultures, all cell numbers were 
normalised to a 20 × 106 inoculum, resulting in a calcu-
lated yield of 778 × 106 (average, range 247–1340 × 106) 
and 218 × 106 MSCs (average, range 130–360 × 106) for 
flask and spinner cultures, respectively (Fig.  2a, b). On 
average 324 × 106 cells (range 220–510 × 106) were cul-
tured in 6  days in the Scinus from a 20 × 106 inoculum 
(Fig.  2c), corresponding to a population doubling level 
of 4.0 (range 3.5–4.7). The highest PDL was observed for 
MSCs grown in flasks (average PDL 5.6 ± 1.8; Fig.  2d). 
Spinner cultures exhibited the lowest expansion (average 
PDL 3.3 ± 0.5; Fig. 2d).
Table 2 Donor information
Donor ID Age (years) Gender Volume (mL) White blood cell count 
(cells/mL)
PDT of second 
passage (h)
1 62 Male 6.1 22.6 × 106 22.9
2 62 Male 13.0 8.5 × 106 29.9
3 57 Male 6.3 12.1 × 106 21.0
4 82 Female 8.0 28.3 × 106 31.1
5 64 Female 10.5 9.0 × 106 34.6
Page 6 of 13Das et al. J Transl Med          (2019) 17:241 
Morphology and confluency
On day 4 and 6 of culture, morphology of the cells and 
confluency of the cultures was analysed. Cells expanded 
on microcarriers retained the spindle shaped morphol-
ogy typically described for monolayer cultures of MSCs 
(Fig. 2e). Microscopic inspection showed that the cells 
were able to occupy freshly added microcarriers. On 
day 6, especially in the spinner cultures, some micro-
carriers were more densely populated than others and 
the cells and microcarriers started to aggregate.
Surface marker expression
The cells harvested on day 6 were evaluated for cell sur-
face marker expression. The frequency of cells expressing 
CD73 and CD90 was the same for the flasks (p = 0.401 
resp. 0.247), spinner and Scinus cultures (Fig.  3a, b). 
We observed a lower frequency of CD105 expressing 
cells in spinner and Scinus cultures, compared to MSCs 
expanded in flasks (Fig. 3c), although this difference was 
not statistically significant (p = 0.245). The frequency of 
 CD3+ T cells was less than 0.01% of the cultured cells 
(Fig. 3d) and was similar for the three culture conditions. 
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In none of the three culture conditions B cells, NK-cells, 
monocytes, macrophages or hematopoietic stem- or pro-
genitor cells could be detected (data not shown).
Since the harvesting procedures for the cells expanded 
on microbeads take a longer amount of time than the 
harvesting procedure for the flask-expanded cells, we 
hypothesized that this difference in downstream pro-
cessing was the cause of the observed phenotype differ-
ence (reduced CD105 expression).  Prolonged exposure 
to pectinase was not considered as a potential cause for 
the reduced expression, since this enzyme is specific to 
the degradation of polysaccharides found in plant cell 
walls. To investigate whether prolonged exposure to the 
cell dissociative reagent TrypLE may explain the reduced 
 CD105+ cell frequency in spinner- and Scinus-cultured 
MSC, a timing experiment was set up as follows. MSCs 
were cultured in multiple flasks until 90% confluency and 
subsequently harvested after various times of incubation 
with TrypLE (up to 120 min). Incubation with trypsin, a 
more aggressive cell dissociative reagent commonly used 
in research, served as a positive control. CD90 and CD73 
median fluorescence intensity (MFI), although different 
for individual MSCs derived from different donor pop-
ulations, was stable for at least 30  min of incubation in 
trypsin as well as in TrypLE (unpublished observation). 
In contrast, CD105 MFI was reduced already after 5 min 
of incubation in trypsin and reached its lowest levels 
after 15 min of incubation. Incubation with TrypLE also 
induced a reduction in CD105 MFI, but this decline was 
slower and steady over 60–120 min time (Fig. 3e). In the 
Flask Spinner Scinus
0
20
40
60
80
100
%
C
D
90
+
M
SC
Flask Spinner Scinus
0
20
40
60
80
100
%
C
D
73
+
M
SC
Flask Spinner Scinus
0
20
40
60
80
100
%
C
D
10
5+
M
SC
a b c
d e
30 60
0
20
40
60
80
100
Incubation time (minutes)
%
C
D
90
+C
D
45
-
30 60
0
20
40
60
80
100
Incubation time (minutes)
%
C
D
73
+C
D
45
-
f g h
5 10 15 20 30 60 120
0
20
40
60
80
Incubation time (minutes)
M
FI
C
D
10
5
(x
10
3 )
MSC 1 Trypsin
MSC 2 Trypsin
MSC 1 TrypLE
MSC 2 TrypLE
30 60
0
20
40
60
80
100
Incubation time (minutes)
%
C
D
10
5+
C
D
45
-
BM-1
BM-2
BM-3
BM-4
BM-5
Flask Spinner Scinus
0.00
0.01
0.02
0.03
%
T
ce
lls
Fig. 3 Identity and purity of the cultured MSCs. a–c Group analysis of expression of CD73, CD90 and CD105 on MSCs harvested from flask, spinner 
and Scinus cultures. d Presence of remaining T cells in the parallel cultures. e Influence of incubation time with cell dissociative reagents on CD105 
expression. f–h Comparison of CD73, CD90 and CD105 surface marker expression after 30 and 60 min of incubation with TrypLE
Page 8 of 13Das et al. J Transl Med          (2019) 17:241 
parallel culture experiments, cells were harvested using 
TrypLE. To investigate whether CD73, CD90 and CD105 
expression was affected by TrypLE incubation time, the 
expression was assessed after 30 and 60 min incubation 
with TrypLE. The proportion of CD73 and CD90 express-
ing cells was not decreased following TrypLE incubation, 
while the proportion of cells expressing CD105 was sig-
nificantly reduced (p < 0.001; Fig.  3f–h). This indicates 
that cell dissociative reagents, including TrypLE, can 
affect MFI levels and that CD105 is more susceptible to 
this effect than CD73 and CD90. Therefore, the observed 
phenotypic difference between flask-and Scinus-cultured 
MSCs is most likely not related to the expansion process, 
but rather to the downstream processing steps used to 
collect the cells.
Differentiation capacity
Differentiation capacity along the three lineages asso-
ciated with MSC phenotype (osteo-, adipo- and chon-
drogenic) was similar for all conditions (Donor 1 results 
shown in Fig. 4). Adipogenic and chondrogenic differen-
tiation was observed for all cells from all different culture 
methods. Osteogenic differentiation was not observed for 
all donors, but differentiation capacity was clearly donor 
dependent, as no qualitative difference was observed 
between culture conditions using the same donor mate-
rial (Additional file  1 shows results for all available 
conditions).
Karyotype
The five Scinus-expanded as well as the five flask-
expanded cultures were analysed by karyotyping for the 
presence of genetically aberrant cells. Although the target 
number of 20 analysable metaphases was not reached in 
the 10 karyotype analyses performed, no signs of genetic 
aberration were observed in any of the MSC populations 
(Table 3).
No differences in immunomodulatory phenotype 
and capacity between Scinus‑, spinner‑ or flasks‑cultured 
MSCs
Response to cytokine stimulation
Upon stimulation with IFNγ, MSCs have been described 
to up-regulate various molecules implicated in MSC-
mediated immunomodulation [14], including CD274 
(PD-L1) and indolamine-pyrrole 2,3-dioxygenase (IDO) 
that are both involved in dampening T cell mediated 
immune responses [15–18]. The flask-, spinner- and 
Fig. 4 Differentiation assay results for Donor 1. Tri-lineage differentiation is observed for all culture conditions for this donor. Results for all donors 
are provided in Additional file 1
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Scinus-cultured cells were investigated for their ability 
to upregulate CD274 and IDO protein expression upon 
stimulation with IFNγ. Both CD274 and IDO expression 
were found to be induced by IFNγ treatment in flask-, 
spinner- and Scinus-cultured MSCs (Fig. 5a, b). A Fried-
man test showed no statistical difference in levels of both 
CD274 and IDO induction between the culture meth-
ods (χ2(2) = 1.600,  p = 0.449 and χ2(2) = 2.333, p = 0.311 
respectively). To further substantiate that such a  poten-
tial difference between culture methods was not missed 
due to measurement inaccuracy a Pearson correlation 
analysis was performed on the small data set (and assum-
ing a normal data distribution). This indicated a strong 
and visual correlation between CD274 and IDO induc-
tion levels in MSCs expanded using the Scinus and using 
Table 3 Karyotype analysis
Number of metaphases
Donor ID Culture method Analysed Result
1 Flask 8 Normal male
Scinus 5 Normal male
2 Flask 17 Normal male
Scinus 0 None
3 Flask 0 None
Scinus 15 Normal male
4 Flask 4 Normal female
Scinus 2 Normal female
5 Flask 10 Normal female
Scinus 16 Normal female
Fig. 5 Immunomodulatory capacity of flask-, spinner- and Scinus-cultured MSC. a, b Induction of CD274 and IDO protein expression in response to 
pro-inflammatory cytokine IFNγ. Induction is expressed as MFI (stimulated cells)/MFI (unstimulated cells). The Friedman test showed no statistically 
significant difference in IFNγ-induced upregulation of CD274 and IDO between cells cultured in different culture conditions, χ2(2) = 1.600, p = 0.449 
and χ2(2) = 2.333, p = 0.311 respectively. The Kruskal–Wallis H test showed a statistically significant difference in IFNγ-induced upregulation of 
CD274 and IDO between MSCs grown from the different bone marrow donors, χ2(2) = 11.500, p = 0.021 and χ2(2) = 11.367, p = 0.023, respectively. 
(a, b inlays) A Pearson correlation analysis confirmed this primary role of donor-related factors in the induction variation by indicating a strong 
correlation between IFNγ-induced upregulation of CD274 and IDO between Flask- and Scinus-expanded MSCs  (R2 = 0.78 and 0.93 respectively). c 
MSC capacity to inhibit T cell proliferation. d Heatmap and cluster analysis of T cell proliferation
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culture flasks  (R2 = 0.78 and 0.93 respectively, inlays 
in Fig.  4a, b). Such correlation indicates that inherent 
donor-related factors mainly contribute to the functional 
differences between samples rather than the culture 
method that was used for expanding the cells.
Inhibition of T cell proliferation
The immunomodulatory capacity of the MSC popula-
tions generated with the three culture methods was 
tested using an in  vitro T cell proliferation assay, in 
which PBMCs were stimulated with anti-human CD3/
CD28 beads in the presence of varying doses of MSCs. 
The capacity of the MSCs to inhibit T cell proliferation 
was similar for all culture methods (Fig. 5c). Accordingly, 
the Pearson correlation average-linkage analysis showed 
no hierarchical clustering by culture method (Fig.  5d). 
Together, we observed no functional differences in MSC-
mediated inhibition of T cell proliferation between MSCs 
that were expanded using the three culturing methods.
Discussion
In this paper we compared key properties of MSC popu-
lations generated with three different culture methods, 
including a novel closed bioreactor system. The goal was 
to investigate the potential of the bioreactor for future 
scale-out of MSC production. For successful scale-out 
of CTMP manufacturing the following aspects are of 
importance: (1) (high) cell numbers are reliably obtained, 
(2) product quality is assured and parity is maintained 
compared to the original process, and (3) production is 
efficient. Our comparative study shows evidence that the 
microcarrier-based bioreactor system meets at least the 
first two criteria. MSCs were expanded in the bioreactor 
to therapeutically relevant cell numbers and the resulting 
MSC populations demonstrated equality to MSC popula-
tions generated with a conventional flask-based process 
with respect to identity, safety and immunomodulatory 
properties.
A novel clinical expansion method has to reliably 
achieve clinically relevant cell numbers. In many cur-
rent clinical MSC applications 1–2 × 106 cells per kilo-
gram recipient body weight are infused. We therefore 
required that a minimum of 200 × 106 cells was reliably 
achieved. This minimum was reached in all bioreactor 
cultures (range 222–510 million). As the cells were still 
steadily expanding at the day of harvest, cell yield might 
be increased with prolonged cell culture. Factors that will 
ultimately limit the maximum yield are the maximum 
concentration of microcarriers, which imposes the maxi-
mum available surface area, and the maximum perfusion 
speed, which determines the rate of nutrient delivery and 
waste removal. It should also be noted that the donor 
material is obtained from relatively old patients (average 
age 65.4 years) with a diseased joint. While these donors 
were chosen because they represent an easily accessible 
donor pool with limited ethical restrictions, they are not 
necessarily representative of the donor populations used 
for clinical applications, especially in allogeneic thera-
pies where MSCs are likely obtained from younger and 
healthy donors.
Continuous growth and high cell numbers were 
achieved using both microcarrier-based methods, but 
traditional flask-based culture displayed slightly faster 
growth. It has been described that expansion of MSCs on 
microcarriers results in a prolonged lag phase compared 
to monolayer culture [19, 20], which could have attrib-
uted to the observed difference in PDL. Another poten-
tial explanation for the difference in observed PDL is the 
lower seeding density that was used for monolayer cul-
ture (400 cells/cm2 instead of 1000 cells/cm2) to prevent 
over confluence at the time of harvest. Seeding density 
can have a measurable effect on growth kinetics, with 
lower seeding densities resulting in faster proliferation 
[21]. Interestingly, the microcarrier culture in the Sci-
nus bioreactor resulted in faster growth than culture in 
the spinners. This difference is most likely attributed to 
the continuously controlled culture environment in the 
bioreactor (maintaining pre-set values for DO, pH and 
temperature). Also, shear forces in the Scinus system are 
low compared to impeller-based bioreactors (manuscript 
submitted) and MSCs are known to be sensitive to shear 
stress, which can affect population doubling times [22].
A recognised issue in microcarrier-based cell expansion 
is aggregate formation, which may compromise bead-to-
bead transfer which is important in the cell expansion 
phase. Microcarrier aggregates may also impair live cell 
harvest efficiency in the downstream processing. In this 
study we obtained single cell suspensions at the end of 
culture, indicating that harvest efficiency was not com-
promised. Minimal aggregation was observed which, 
combined with a straightforward harvesting procedure, 
resulted in easy cell collection.
MSCs have been defined by the presence and absence 
of a specific set of surface markers, their ability to adhere 
to plastic and a tri-lineage differentiation potential, which 
is based on MSC expansion in tissue culture flasks [23]. 
MSCs expanded using the three culture methods were 
morphologically similar, adhered to plastic and expressed 
CD73, CD90 and CD105, and maintained their differen-
tiation potential in accordance with these criteria. The 
cells did not display a method-related qualitative differ-
ence in differentiation capacity between culture condi-
tions. We demonstrated robust differentiation along the 
chondrogenic and adipogenic lineage for all donors and 
all conditions. Osteogenic differentiation was only clearly 
observed for Donor 1. Other donors displayed minimal 
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to no osteogenic differentiation, but again no difference 
was observed between the culture conditions. Although 
expression of CD73 and CD90 was similar between the 
culture methods, individual cell preparations harvested 
from the Scinus bioreactor displayed a reduced fre-
quency of  CD105+ cells. Reduced expression of CD105 
in bioreactor cultures has been reported before [24, 25]. 
We demonstrated that CD105 is susceptible to degra-
dation by the enzyme used in the harvesting process, 
explaining the lower CD105 expression levels. Indeed, 
CD105 expression levels were restored after subsequent 
expansion and harvesting from flasks (data not shown). 
Thus far, there is no clinical relevance to the expression 
of CD73, CD90 and CD105 on MSCs, and the expression 
has rather been used as a characteristic phenotype of the 
cells. Therefore, it seems arguable to adhere to this crite-
rion to define MSCs. The MSC criteria previously defined 
have served a good purpose in the flask-based expan-
sion era, but need to be revisited now that more efficient 
selection and expansion methods become available.
The cell populations cultured with either method did 
not show differences with respect to the fraction or com-
position of cellular impurities. Also the karyotypic analy-
ses did not show a compromised genetic profile for either 
of the culture methods. Therefore, the data collected in 
this comparative study, indicate a comparable purity and 
safety profile for the three production methods.
MSCs cultured with the bioreactor system showed 
equality to flask-expanded cells with respect to their 
immunomodulatory properties. IFNγ-induced expres-
sion of CD274 (PD-L1) and IDO, molecules that are asso-
ciated with functional inhibition of immune responses 
[15, 26], was observed for all cultures. Previously, inter-
donor variation in the levels of such upregulation has 
been reported [27]. This phenomenon was also observed 
in our study, both in the flask cultures as well as in the 
microcarrier-based cultures. Our IFNγ-induced immu-
nomodulatory molecule expression data indicate that 
attributes of MSC populations are more influenced by the 
starting material than by the culture method and indicate 
parity between the MSC populations resulting from flask 
and microcarrier-based culture methods.
For logistical reasons our IFNγ-stimulation assay was 
preceded by an extra plating and culturing step on a flat 
surface. Although all induction attributes were therefore 
measured on flat surface-expanded cells, our results indi-
cate that the preceding expansion on microcarriers does 
not lead to irreversible changes, whereas donor-depend-
ent differences seem to be preserved.
Inhibition of T cell proliferation is the most com-
monly tested MSC function relevant for the proposed 
mechanisms of action of MSCs in various clinical trials 
aiming at immunoregulation [28]. The inter-donor vari-
ation in IFNγ-induced expression levels did not trans-
late into significantly different functionality in an 
in  vitro assay measuring the capacity to inhibit T cell 
proliferation. Our data, therefore, do not support a 
direct link between responsiveness of CD274 or IDO 
expression to IFNγ and the capacity to inhibit T cell 
proliferation.
Manufacturing efficiency is the third crucial aspect 
for the viability of cell therapies as a whole. Previous 
pioneering therapies involving expensive production 
processes have failed due to unfavorable cost–benefit 
assessments and lack of reimbursement [29]. There-
fore, there is a clear need for alternatives to traditional 
labor-intensive flask-based cell expansion processes. 
The use of closed, automated and controlled devices 
is seen as an important step that facilitates affordable 
cell expansion within GMP regulations [30]. The use 
of such systems has several benefits: (1) a closed sys-
tem minimizes the risk of contamination, providing 
options to ultimately manufacture CTMPs outside of 
stringently controlled and expensive cleanroom class B 
environments, (2) the automation reduces labor costs 
and process variability [25], (3) the controlled envi-
ronment within the device provides more accurate 
information about the state of the cell cultures. This 
information can be used to improve and further stand-
ardize the expansion process. All these factors will lead 
to more robust production processes at reduced costs. 
We initiated cultures with pre-cultured cells to obtain 
sufficient cells to seed all conditions and we chose 20 
million cells as a starting inoculum since this amount 
was previously used as an inoculum for other bioreac-
tor studies [25, 31]. The total cell numbers achieved in 
our study (average 324 million cells) would require an 
equivalent of 130 T175 flasks, an amount that requires 
multiple operators to refresh and harvest in a realistic 
time-frame. In contrast, the total volume of the biore-
actor can be refreshed and harvested by one operator 
within 10 min and 1 h respectively. An interesting fea-
ture of the Scinus bioreactor is the option to culture at 
any volume between 100 to 1400 mL or to increase the 
volume of the bioreactor bag during the process. This 
allows the seeding of very low cell numbers at manu-
facturing start. Currently, protocols using this feature 
are being optimised to generate clinically relevant MSC 
numbers from a single BM biopsy. In these protocols 
the culture volume is gradually increased and MSC 
colonise freshly added microcarriers by bead-to-bead 
transfer [32, 33]. These versatile properties make the 
medium-sized Scinus bioreactor particularly suited for 
production scale-out.
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Conclusion
We demonstrated that a new microcarrier-based biore-
actor system fulfils essential requirements to consider its 
integration in the further development and scale-up of 
flask-based MSC manufacturing methods. This system 
allows MSC expansion to clinically relevant cell numbers, 
and the resulting cell populations are similar in identity, 
purity and potency to MSCs expanded in traditional 
flasks. The system has the potential to efficiently scale-
out the production of MSCs for clinical applications.
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